EMBLA.CO Embla Medical hf

Healthcare Medical Devices Copenhagen Exchange
27.05 DKK
Close of Oct 29, 2026
25.90 37.90
Market cap
DKK 11.5B
P/E
19.0x
P/B
1.82x
ROE
10.0%
Dividend yield
-
Fundamental score
2.9/5

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is EMBLA.CO undervalued?

Graham number
Price27.05
Graham value21.78
Premium24.2%

EMBLA.CO trades 24.2% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Embla Medical hf fundamental analysis

14 of 22 checks passed

ROE 1/2

Moderate return on equity (10.0%), between 10% and 20%.

ROA 1/1

Return on assets (5.6%) is above the industry median (-7.4%).

Profit Consistency 2/2

Profitable for 10 consecutive years.

Earnings Growth 5Y 1/1

Earnings per share grew over the past 5 years.

Earnings Acceleration 0/1

Last year's EPS growth (26.5%) is not above the 5-year average (69.0% a year).

Earnings Growth vs Industry 1/1

Last year's EPS growth (26.5%) is above the industry median (5.2%).

Revenue Growth 2/2

Revenue grew 10.3% a year over the past 3 years.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 1/2

Moderate debt to equity (51.9%), up to 100%.

Debt Trend 1/1

Debt to equity has not risen over the past 5 years.

Debt Coverage 1/1

Operating cash flow covers 20% of total debt.

Interest Coverage 1/1

EBIT is 6.8x against interest expense, well covered.

PE vs Market 0/1

PE (19.0x) is above the market median (17.0x).

PE vs Industry 0/1

PE (19.0x) is above the industry median (19.0x).

PBV 1/1

Price to book (1.8x) is below the industry median (2.5x).

Graham Number 0/1

The price is above the Graham number (PE x PB = 34.7, limit 22.5).

PEG 1/1

PEG on 5-year earnings growth is 0.28, growth is cheap.

Dividend Yield 0/2

No dividend paid in the last reported year.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 0/1

No dividend, or no profit to pay it from.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Embla Medical hf stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Embla Medical hf

Embla Medical hf., together with its subsidiaries, provides non-invasive orthopedic products in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. It operates through three segments: Prosthetics and Neuro Orthotics, Bracing and Supports, and Patient Care. The Prosthetics and Neuro Orthotics segment offers mechanical products, such as lower and upper limb loss or difference; and bionic products, such as microprocessor-controlled feet, knees, hands, fingers, …

Full company profile